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Background: Plasmodium vivax, the most geographically distributed cause of malaria, accounts for more than 70%
of cases in the Americas. In Colombia, P. vivax was responsible for 67.3% of cases in the last five years. Despite vivax
malaria impact worldwide, historically it has been neglected and considered to be a benign disease. In the last
decade medical literature reports have emerged countering this benign outlook. This study pretends to describe
the clinical and paraclinical profile of severe vivax malaria cases hospitalized in Tumaco, Cali, Buenaventura between
2009 and 2013, to contribute to the knowledge regarding the behaviour and clinical expression of this disease.
Methods: This is a descriptive, retrospective case-series study of 16 severe malaria vivax cases, hospitalized between
2009 and 2013, in Colombian municipalities of Tumaco, Buenaventura and Cali. Severe malaria vivax cases were
defined using criteria adapted from the national guidelines. Descriptive analyses of reason for consultation, signs and
symptoms, diagnosis, treatment, paraclinical characteristics, complications, and time hospitalized, were conducted.
Results: Sixteen cases of severe P. vivax were analysed. Fever, chills and headache were shown to be the main
admission symptoms. Elevation of total bilirubin levels in 18.75%, and severe thrombocytopaenia in 25% of cases were
the main complications presented during hospitalization. All cases responded to treatment, there were no deaths.
Conclusions: The following questions derived from this study could be the basis for future research: 1) Does the time
to consultation have an impact on the number of days hospitalized and how cases progress during hospitalization,
2) Are the severity criteria in WHO guidelines sensitive enough to be used in clinical practice compared to national
guidelines, and 3) How does malnutrition contribute to anaemia in malaria-endemic regions.
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Malaria, one of the most important parasitic diseases
of the 21st Century, is caused by parasites of the genus
Plasmodium [1]. The disease significantly impacts global
health; in 104 malaria-endemic countries where an
estimated 207 million cases (135–287 million) and an
estimated 627,000 deaths (473,000-789,000) have been
reported in 2012 [2].
Currently Plasmodium vivax is the most geographically-
distributed cause of malaria worldwide. Although, estimates
vary, it is projected that 2.85 billion people live at risk [3],* Correspondence: sanmart79@gmail.com
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unless otherwise stated.and annual infections range between 132–391 million
[4,5]; in the Americas, about 5.5% of people are at-risk [6],
and P. vivax accounts for more than 70% of cases [7].
Furthermore, in the Americas about 30% of the popula-
tion of the 21 countries with active transmission are at
some degree of risk; Brazil and Colombia accounted for
68% of the cases in 2011 [2].
In Colombia, approximately 27 million individuals live
in areas suitable for transmission [8], and, although the
mortality of the disease has diminished, the associated
morbidity has remained relatively constant, with a national
registry of 378,764 cases, of which 1,800 were severe in
the last five years, whereas P. vivax was responsible for
67.3% of all cases [2,9,10].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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state) on the Pacific coast, are the most representative
sites for high intensity transmission [8]. Buenaventura is
at 7 metres above the sea level, average temperature 27°C,
6,500 mm annual rainfall. Cali is located at an altitude of
995 metres above sea level, on average the temperature is
23°C, the average annual precipitation is 1,000 mm in
most of the metropolitan area, Tumaco is located 3 metres
above sea level the average temperature ranges between
26 to 28°C, [11-13]. Buenaventura, Cali and Tumaco, have
unique characteristics that make the transmission and
proliferation of Plasmodium species more prominent, and
are considered endemic areas of malaria.
Despite vivax malaria significant contribution towards
the overall case count worldwide, historically it has been
neglected and considered to run a benign disease course
compared to falciparum malaria. This has led to reduced
interest in research, funding, control strategies, health
and socio-economic impact evaluation [5,14-17].
In the last decade, increasing reports in medical litera-
ture have emerged to globally counter the benign outlook
on P. vivax, documenting clinical outcomes perceived to
be principally of P. falciparum, including cerebral malaria,
hydrocephalus, retinal haemorrhage, myocarditis, acute
respiratory distress, pulmonary oedema, gastro-intestinal
symptoms, jaundice, hepatic dysfunction, acute kidney
injury, severe anaemia, neutropaenia, thrombocytopaenia,
haemoglobinuria, hypoglycaemia and shock [17-24].
Data supplementing and interpreting the increase in
severe vivax malaria cases are scarce, additionally, caution
is required due to weighty contributory factors, such as its
relapsing nature due to hypnozoites, incidental parasit-
aemia, co-morbidities, treatment resistance, and access to
opportune healthcare [22,25].
As of 19th March 2014, the search within the US National
Library of Medicine National Institute of Health database
for severe malaria due to P. falciparum retrieved almost
seven times more abstracts than for severe malaria due to
P. vivax. This situation highlights the urgency to investigate
in depth severe malaria cases due to P. vivax.
Therefore, this study intends to establish the clinical
and paraclinical profile of severe malaria vivax cases hos-
pitalized in Tumaco, Cali, and Buenaventura between
2009–2013, to contribute to the knowledge regarding the
behaviour and clinical expression of this disease.
Methods
Study design
This is a descriptive, retrospective case-series study of 16
severe malaria vivax cases, hospitalized between 2009 and
2013. The data were mined from medical records revised
at four hospitals located in endemic areas of the Colombian
states of Nariño and Valle del Cauca, covering the munici-
palities of Tumaco, Buenaventura and Cali.Medical doctors were employed and trained in order
to fill out a virtual instrument accessible via email. The
instrument included the following information: personal
identification, past medical history, history of present ill-
ness, clinical characteristics, physical examination, diagno-
sis, paraclinical and parasitological results on admission,
treatment and case outcome.
To assure that the instrument was filled out correctly,
three independent reviewers evaluated the quality of the
information filled out for each medical report and pro-
vided feedback when necessary to correct discrepancies.
This was carried out at least twice, before and after
feedback.
Frequencies, central tendency and dispersion were cal-
culated. Median and comparison of frequencies was used
to analyse the data. Descriptive analysis was processed
using STATA® version 12.
Variables considered in the descriptive analysis were:
gender, age, place of origin, duration of symptoms be-
fore admission, symptomology on admission, presence
of co-morbidities, days hospitalized, vital signs on
admission, thick and thin blood smear slide results,
physical examination on admission, medical treatment
received, initial laboratory values, parasitaemia, complica-
tions during hospitalization, pregnancy status, previous
history of malaria, and prior medical attendance before
admission.Case definition of severe vivax malaria
Subjects hospitalized between 2009–2013, with diagnostic
confirmation of P. vivax via thick blood smear slides, and
with one or more of the clinical or paraclinical criteria
mentioned in the Colombian national guidelines for
severe malaria, were defined as cases (Table 1).
The Colombian National guidelines for severe malaria
define hepatic dysfunction as transaminase values >40 IU.
According to medical literature and the WHO malarial
hepatic dysfunction is defined as an elevation of three
times the upper limit of normal transaminase values
[26,27]. An intermediate value of >80 IU was utilized in
this study [27-29].Exclusion criteria
Cases with sickle cell disease, viral or bacterial infections
and/or other diseases that could explain the clinical
presentation were excluded, as well as cases that origi-
nated from a municipality not included within the area
of analysis, or cases that were transferred from another
municipality to receive medical care.
Ethical approval for access to patient medical history
data and extraction for analysis and conversion to scientific
manuscript was approved by the Ethical Committee of
Hospital Fundación Santa Fe de Bogotá.
Table 1 Criteria used to define severe malaria cases according to national guidelines
Clinical criteria* Laboratory criteria*
1. Loss of consciousness or profound coma 1. Haemoglobinuria
2. Prostration; extreme weakness with inability to walk or
sit without assistance
2. Hypoglycaemia (<60 mg/dl)
3. Inability to feed oneself 3. Metabolic acidosis (plasmatic bicarbonate <15 mmol/L)
4. Multiple seizures; more than 1 episode in 24 hours 4. Hyperlactaemia (lactate acid <5 mmol/L)
5. Respiratory distress syndrome 5. Severe anaemia (haemoglobin <7 g/dL, haematocrit <21%)
6. Circulatory collapse/shock; systolic arterial pressure
<80 mmHg in adults and <50 mmHg in children
6. Hyperparasitaemia (>50,000 asexual parasites/uL) with the
diagnosis of P. falciparum, or mixed infection with P. vivax
7. Clinical jaundice with signs of vital organ failure 7. Thrombocytopaenia (<50,000 mm3)
8. Spontaneous haemorrhage 8. Elevated transaminase (>80 IU)
9. Pulmonary oedema evidenced through radiography 9. Elevated total bilirubin (>1.5 mg/dL)
10. Renal insufficiency (serum creatinine level >1.5 mg/dL)
*Ministry of Social Protection. Republic of Colombia. Public Health General Management. National Institute of Health. World Health Organization: Guideline for the
integral clinical treatment of patients with Malaria. Bogotá; 2010 [41].
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Demographic characteristics
In total there were 16 cases of severe vivax malaria iden-
tified, 11 cases were from the municipality of Tumaco,
three cases from Cali and two cases from Buenaventura.
The median age was 23.5 years (range: five to 57 years).
Demographic characteristics regarding the 16 cases are
further detailed in Table 2.
Past medical history
With regard to existing co-morbidities, one case had a
medical history of secondary arterial hypertension, non-
specified diabetes mellitus, and cerebrovascular disease.
Fifty percent (8/16) of the cases had no previous history
of malaria or blood transfusion in the previous month,
and there was no data available for the remaining eight
cases. Before reaching a site where medical care was avail-
able, 18.8% (3/16) of the cases did self-medicate. Of the
three cases that self-medicated, two used paracetamol and
one was unclear about which medication was used. Two
of the cases were pregnant women.
Signs and symptoms on admission
The median period of time with symptoms before medical
attendance was five days (range: three to 31 days). Fever
and chills were the most ubiquitous symptoms, present in
all cases. Headache, myalgia, arthralgia, asthenia and
adynamia were the following most frequent symptoms
as mentioned in Table 3. Dry cough was only present in
6.3% (1/16), while vomiting, was present in 25% (4/16)
and abdominal pain in 25% (4/16). Urological symptoms
were present in two cases. One case presented polyuria
and dysuria, and one case presented dark urine. Haem-
orrhagic symptoms were alluded to in 12.5% (2/16)
cases, one of the cases presented haematochezia and in
the other case epistaxis. There were no referred severeneurological, otorhinolaryngological, or constitutional
symptoms.
At the time of admission all the cases were alert (16/16).
Out of the 16 cases, six were dehydrated, eight were
hydrated and there is no register for two cases. Ad-
equate diuresis was annotated in eight cases; data were
not available for the remaining eight cases. Oral toler-
ance was registered in 93.75% of cases, data were not
available for the remaining cases; it was also confirmed
that in the 24 hours prior to the physical examination
no case presented more than five emetic or diarrhoeic
episodes. Out of the 16 cases, four presented hepatomeg-
aly, and two cases had splenomegaly. Jaundice was found
in five cases. No signs of severe neurological or pulmonary
compromise were evident.Vital signs on admission
The median body temperature was 37.0°C (range: 34.5-
39.5°C), the systolic/diastolic pressures ranged between
60/20 and 140/90 mmHg, with a median of 105/70. Out
of the 16 cases, the median heart rate was 89.0 BPM
(range: 70–140 BPM), and the median respiratory rate was
21.0 RPM (range: 16–32 RPM). Further information about
the description of vital signs on admission is presented in
Table 3.Malaria diagnosis
Methods used to diagnose malaria involved peripheral
film, both thick and thin blood smear. No other form of
diagnosis techniques for malaria were utilized. P. vivax
was identified for all cases (16/16). One case was diag-
nosed with thin blood smear while 93.8% (15/16) were
diagnosed with thick blood smears. Parasite count was
registered for 15 out of 16 cases. Non-specified parasite
count median was 6,720 p/uL (range: 320–36,500 p/uL).
Table 2 Sociodemographic characteristics of the 16
severe vivax malaria cases
Age (years) n (%)
2 to 9 2 (12.50)
15 to 19 4 (25.00)
20 to 29 6 (37.50)
30 to 39 1 (6.25)
40 to 49 2 (12.50)






















Street vendor 1 (6.25)
Manucurist 1 (6.25)
Not available 7 (43.75)
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made for 62.5% (10/16), 25% (4/16) of the cases were
thought to be febrile syndrome of unknown origin, 6.3%
(1/16) gestational hypertension, and 6.3% (1/16) was sus-
pected to be dengue with warning signs.
Paraclinical results on admission
All cases were evaluated with a haemogram at the time of
admission. Haemoglobin median was 10.7 g/dL (range:
6.2-15.0 g/dL;), haematocrit median was 34.2% (range:
18.1-43.6%), platelets median value was 91,500 mm3
(range: 25,000.-328,000 mm3). leucocytes median value
was 5,935 mm3 (range: 2,500-10,800 mm3), while median
for lymphocyte and neutrophil count was 37.55% (range:
6.0-69.4%) and 49.6% (range: 12.5-94.0%), respectively.Due to the retrospective nature of the study, register
of renal function tests, liver function tests, and other
paraclinical test are not available for all the cases. Gly-
caemia was measured on entry in 56.3% (9/16) cases,
transaminases were measured in 50% (8/16), total biliru-
bin was measured in 25% (4/16) cases, creatinine was
measured in 81.25% (13/16) cases and uri-analysis was
undertaken in 68.75% of cases (11/16).
The median blood glucose level was 109 mg/dL (range:
74–169 mg/dL), the median value for total bilirubin was
four mg/dL (range: 2–5.6 mg/dL), alanine aminotransfer-
ase (ALT) and aspartate aminotransferase (AST) median
value was 24 IU (range: 10–381 IU) and 29 IU (range:
21–377 IU) respectively, creatinine median value was
0.9 g/dL (range: 0.5-1.6 g/dL). Out of the 11 urinalysis
registered, nine were normal, one case had proteinuria
and another case presented haematuria. Haemoglobinuria
was not observed in any of the cases.
Further information about paraclinical results can be
found in Table 4.
Treatment received during hospitalization
All prescribed medication was available for use by medical
staff, and all medication administered was in accordance
with the prescribed scheme. Anti-malarial treatment re-
gimes consisted primarily of primaquine 93.8% (15/16)
and chloroquine 87.5% (14/16), followed by clindamycin
18.3% (3/16), artemether-lumefantrine 12.5% (2/16), quin-
ine 6.3% (1/16), and artesunate 6.3% (1/16). Doxycycline
was not used in any of the cases. 87.5% (14/16) of cases
received oral medication, while 12.5% (2/16) received
treatment intravenously, after which they were switched
to oral treatment. The median number of days with intra-
venous medication was five (range: 4–6 days), while the
median number of days on oral treatment was seven days
(range: 7–20 days). Physical mediums to reduce fever were
used in all cases.
Hospitalization data
The median number of days hospitalized was four (range:
1–8 days), 25% (4/16) of cases were treated in the inter-
mediate care unit. Intermediate care unit cases had a
higher median number of days hospitalized of 4.5 days,
and ranged between four and six days hospitalized.
Complications developed during hospitalization
None of the cases presented haemoglobinuria, respiratory
difficulty, altered mental status, prostration, seizures, in-
ability to feed or hyperparasitaemia. Hyperlactataemia,
metabolic acidosis and pulmonary oedema were not
reported in the medical records, there was no evidence of
arterial blood gases or chest x rays.
Nine from the 16 cases presented anaemia during
hospitalization of which 22.2% (2/9) had severe anaemia,
Table 3 Description of cases














Hydrated Jaundice Hepatomegaly Splenomegaly Complications
during admission
and hospitalization
1 Fever, chills, myalgia,
asthenia, adynamia
Vivax malaria 36.0 70 20 110/70 Yes No No No Elevated transaminase
2 Fever, chills,
headache, myalgia
Vivax malaria 37.6 76 22 100/90 Data not
available
Si Si No Acute renal failure,
elevated bilirubin, jaundice










Vivax malaria 39.2 92 29 100/50 Data not
available
No Si No Elevated bilirubin





6 Fever, chills, headache,
myalgia, asthenia,
adynamia
Febril syndrome 39.0 140 24 Data not
available







Vivax malaria 37.4 84 20 110/70 No Si No No Elevated transaminase,
jaundice with evidence
of organ failure
8 Fever, chills, headache, Febril syndrome 39.0 104 32 60/20 No No No No Shock, thrombocytopaenia
9 Fever, chills, myalgia,
asthenia, adynamia
Vivax malaria 34.5 88 22 110/80 Yes No No No Thrombocytopaenia
10* Fever, chills, headache,
asthenia, adynamia
Febril syndrome 37.0 100 22 100/60 Yes No No No Elevated bilirubin
11 Fever, chills,
asthenia, adynamia
Vivax malaria Data not
available
80 19 110/70 Yes Si No No Elevated bilirubin,
jaundice with evidence
of organ failure
12 Fever, chills, headache,
asthenia, adynamia
Vivax malaria 36.5 90 18 100/50 Yes Si Si Si Shock
13 Fever, chills, headache,
asthenia, adynamia
Vivax malaria 37.0 88 22 120/80 Yes Si Si No Thrombocytopaenia
14 Fever, chills, headache Vivax malaria 37.0 117 28 Data not
available




Febril syndrome 39.5 80 19 110/70 No No No No Elevated bilirubin






















Table 4 On admission paraclinical results






1 13.65 41.71 120,000 5,370 54.50 27.90 Data not available Data not available 1.00
2 14.60 43.60 169,000 8,880 20.00 74.70 38.00 32.00 1.60
3 12.10 34.30 82,000 8,100 38.50 41.00 381 377 0.50
4 8.80 Data not available 73,500 10,800 29.00 52.00 Data not available Data not available 0.70
5 14.83 41.08 42,000 5,800 27.60 59.40 Data not available Data not available 0.90
6 11.00 Data not available Data not available 3,260 43.00 57.00 Data not available Data not available Data not available
7 10.40 32.00 118,000 3,220 25.40 68.30 Data not available 189 1.10
8 7.97 25.78 25,000 5,080 36.60 47.20 21 31 1.04
9 11.17 34.20 47,000 2,500 50.40 29.10 23 29 0.90
10 9.30 28.20 69,000 4,200 49.00 35.60 49 28 0.50
11 9.99 29.00 101,000 3,760 24.00 62.00 25 21 0.70
12 15.00 Data not available 105,000 8,500 6.00 94.00 Data not available Data not available 1.00
13 10.00 34.40 43,000 7,960 43.00 44.70 Data not available Data not available Data not available
14 6.51 18.88 317,000 6,070 69.40 12.50 Data not available Data not available 1.00
15 11.36 35.14 150,000 10,800 66.00 25.20 Data not available Data not available Data not available
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Jaundice was presented in five out of 16 cases; it was
consider a severity sign in three cases due to the pres-
ence of jaundice plus signs of organ dysfunction. Fur-
ther information about complication developed during
hospitalization is summarized in Table 5.
Discussion
Information from medical records of sixteen cases of
severe vivax malaria hospitalized in the municipalities of
Tumaco, Cali, and Buenaventura, between 2009 and
2013 was collected retrospectively. The majority of the
cases originated from Tumaco, one of the cases presented
comorbidities that didn’t seem to affect its outcome.
Principal symptoms found at time of admission were
fever, chills, and headache. Main complications found
were: hyperbilirubinaemia, thrombocytopaenia and jaun-
dice with evidence of organ dysfunction. Most of the cases
received Chloroquine and primaquine as main treatment.
The Pacific Colombian geographic region has socio-
economic and environmental conditions able to the
transmission of malaria species as described by Arevalo.
et al. [8,11]. Plasmodium vivax is the most prevalent
malaria parasite in Colombia, even though P. falciparum
has been described as the main cause of severe malaria
and malaria caused by P. vivax has been considered a
benign condition, this outlook has been challenged in
the last decade, and complications have been described
[18,30].
According to the literature, cases that had malaria and
one or more co-morbidities tended to develop more
complications and severe presentations [24,26,31]. From
the 16 cases described, only one case was diagnosed with
arterial hypertension, diabetes mellitus and cerebrovas-
cular disease. Despite the presence of co-morbidities, noTable 5 Frequency of complications presented on
admission or during hospitalization
Complications n %
Spontaneous bleeding 2 12.50
Shock: Systolic pressure <80 mm/Hg (adults),
<50 mmHg (children)
3 18.57
Severe normocytic anaemia: Haemoglobyn
<7 g/dL, hematocryte <21%
2 12.50
Hypoglaecemia <60 mg/dL 1 6.25
Acute renal failure: Creatinine >1.5 mg/dL 1 6.25
Elevated aminotransferase >80 U.I. 3 18.75
Hyperbilirubinemia: Total bilirubin >3 mg/dL 6 37.50
Thrombocytopaenia <50,000 mm3 4 25.00
Jaundice with evidence of organ dysfunction 3 18.57
One complication (8/16; 50.00%)
More than one complication (8/16; 50.00%)evidence of any particular pattern of increased complica-
tions during hospitalization was found.
The symptoms that were mentioned by cases were
concordant with symptoms most frequently mentioned in
medical literature, such as fever, chills, headache, muscu-
loskeletal pain, asthenia, and adynamia [8]. Respiratory
and gastrointestinal symptoms were not as frequently
mentioned by theses cases. Presence of pruritus was
exclusively reported in pregnant cases, as an incidental
symptom.
Of particular interest was the presence of hepatomegaly
in four cases, jaundice in five cases, elevated transaminase
in three cases, and elevated bilirubin values in six cases,
which had been reported in the literature as common
signs and laboratory values associated with a complication
of vivax malaria [7,21,27,30,32].
With regard to vital signs, it was observed that the
median body temperature was 37.0°C, which is lower
than expected value for a case with malaria. This may
confuse diagnosis and delay treatment. Although there
were only three cases that reported self-medication, data
was not available for almost half of the cases (7/16); it is
possible that antipyretic use prior to consultation masked
the fever. A certain degree of immunity in endemic areas
has also been suggested as cause of afebrile infection and
low severity of symptoms [8].
Malaria diagnosis was suspected through signs and
symptoms mentioned above, to confirm the diagnosis all
cases underwent paraclinical evaluation through blood
smear. Thick blood smear was used in 15 cases, while
thin blood smear was used in one case. These methods
are widely available in endemic regions in Colombia due
to their low costs, despite the existence of more sensitive
and specific diagnostic tests [29,33].
Additional paraclinical data were registered to comple-
ment the medical evaluation and asses malaria severity.
Anaemia, thrombocytopaenia, hepatic dysfunction, acute
renal failure, hypoglycemia were evidenced.
Severe anaemia is described in literature as one of the
main severity complications of endemic regions [8,32].
Anaemia was found in nine of the 16 cases, two of them
were considered severe anaemia (haemoglobin <7 mg/dL)
and required blood transfusion.
Given the socio-economic conditions of the population,
it is difficult to associate anaemia solely with P. vivax, as
other factors, such as malnutrition, could have influenced
the presence of anaemia [34-36]. Currently the literature
on this topic in Colombia is scarce, or focused in children
and thus should be studied.
Low platelet count is been considered a common com-
plication presented in severe vivax malaria, and causal
factor of mucosal bleeding [37]. 25% of the cases had a
count below 50,000 mm3 and only two cases reported
haemorrhagic manifestations. Renal damage was found
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levels were slightly above normal range, another explan-
ation for this increment could be dehydration.
None of the cases presented signs of pulmonary oedema
or acute respiratory distress syndrome, therefore, there
was no indication to order chest X ray to rule out the
complication. Müller et al. consider the low rate of pul-
monary signs to be a result of cases residing in an endemic
region, where they develop protective immunity, reducing
these pulmonary complications [7,27].
Hepatic dysfunction, represented principally as an
elevation of total bilirubin value, was the foremost sali-
ent criterion for diagnosis of severe vivax malaria. As
described in the literature, elevation of bilirubin has
been associated with anaemia and thrombocytopaenia
[27,29,38]. In this study 25% of cases presented anaemia
and elevated bilirubin levels.
According to the World Health Organization (WHO)
international guidelines [39], hepatic complication was
present in two cases; one case had total bilirubin levels
above 3 mg/dl, and had a three fold elevation of trans-
aminase normal value while the other case only presented
total bilirubin levels greater than 3 mg/dl.
In agreement with the literature, the WHO criteria are
too demanding, resulting in a low detection sensitivity
[28,40]. Additionally, the national guideline criteria of
abnormal hepatic dysfunction are 3,5 times more sensitive
than the WHO criteria. For this reason, it was decided to
utilize an intermediate value for transaminase values of
80 IU to classify abnormal hepatic dysfunction [28]. No
cases presented with acute hepatic failure as defined by
King’s College criteria [41].
With regard to treatment, all prescribed medications
were available and administered in a timely manner. In
Colombia, the first-line treatment for non-severe malaria
is chloroquine and primaquine. Despite reports of resist-
ance since 2001, it appears to be effective for vivax infection
[42-44]. The first-line treatment for severe malaria is
intravenous artesunate, followed by combined oral
treatment artemether and lumefantrine. Pregnant women
should receive combined treatment with quinine and
clindamycin [42].
Chloroquine and primaquine were the most prescribed
medications, 93.8% (15/16) and 87.5% (14/16), respect-
ively, which suggests that the cases are being treated as
non-severe malaria. Clindamycin was prescribed in three
cases and quinine was prescribed in one case; the two
pregnant cases did not receive medication indicated by
national guidelines. Artemether-lumefantrine was only
prescribed for two cases and only one of the cases received
artesunate. All cases received antipyretic and crystalloids
during hospitalization. Other forms of medication received
included gastric mucosal protective agents, followed by
analgesics and then diuretics.Despite chloroquine and primaquine not being recom-
mended in national guidelines for severe P. vivax cases,
there was a notable reduction of symptoms and disease
progression, which was related to a positive outcome in
all cases.
Limitations of the study include quantity, distribution
of cases obtained, which did not represent the estab-
lished rates of infection in Colombia or reported vector
behaviour. The retrospective nature of the design of the
study used to collect data was a limitation within itself.
Most of the medical records reviewed were handwritten;
only in 2013 were the majority of visited hospitals begin-
ning to utilize electronic medical records. This limited the
mining of data due to the high proportion of incomplete,
fractionated or illegible medical records before 2013, thus
explaining in part the concentration of data in 2013.
In agreement with Tobón, et al., the fact that cases
seek medical attendance at different stages of the disease
could imply that some symptoms of severity might be
present while others are not at the time of admission
[27]. This could have led to different approaches towards
case diagnosis, treatment and paraclinical examination
possibly explaining the disparity in data between cases.
Conclusion
This retrospective case-series of 16 hospitalized cases of
vivax malaria was written to contribute to the knowledge
regarding the behaviour and clinical expression of this
disease. A predominance of fever, chills and headache as
admission symptoms was evidenced, and an elevation of
total bilirubin levels, and severe thrombocytopaenia were
the main complications presented during hospitalization.
All cases responded to treatment, there were no deaths.
Questions arising from this study that can be followed
up to include: 1) If the time to consultation has an impact
on the number of days hospitalized and how cases pro-
gress during hospitalization 2) If the severity criteria in
WHO guidelines is sensitive enough to be used in clin-
ical practice, versus national guidelines, and 3) If there
is a particular role that malnutrition contributes to in
malaria-endemic regions that suffer from anaemia.
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